Our focus is on neurochemicals acting on the peripheral and central nervous system

We are enthusiastic about neurochemicals acting as agonists or antagonists on G-protein coupled receptors located in the peripheral and central nervous system. Our goal is to address the clinical needs to diagnose and treat the neurological pathologies at the origin of the disease; thus, avoiding a merely systematic treatment and rather stopping or delaying disease progression.

The chemical structure of small molecules is the key for successful drug design and development for both imaging probes and therapeutics. The combined, interdisciplinary knowledge of medicinal chemists, pharmacists and physicians allows drug adjustment and pave the way towards the application of our substances as tools for image-guided therapy.

The bottleneck of the drug development process is the preclinical screening of a compound library, as we still lack substantial methods for a fast and reliable biological assessment. We developed a complex dynamic 3D-cell culture method, which mimics the tissue situation and has the potential to fasten the screening process. Moreover, it conforms with the 3Rs (reduce, replace, refine) rule in animal ethics and will contribute to reduce the number of animals needed in drug testing.

Our main interests lie in

  • Inventive drug and tracer development of neurochemicals
  • Innovative drug screening methods
  • Interdisciplinary approaches close to medical application

EANM 2021 Plenary Lecture - Isotopes Past and Future

Missed the EANM 2021 plenary lecture on the availability of medicinal radioisotopes.

You can still watch it here.

CBmeds microONE promo video

For the SDG-3 presentation at the austrian parlament, our consortium of the FFG funded microONE project (CBmed, Univie, MUW, among others) produced a nice promo-video. Thank you to Thomas Wadsak for the nice production. (German only)

News and announcements

22.05.2025
 

Our group had a successful week at the ISRS meeting at Gold Cost, Australia. With one oral presentation on sustainability, a rapid fire and a poster presentation. Thanks for the great organisation of the meeting.

22.05.2025
 

We have a new Master of Science in our group! Congratulations to Laura Naprudnik. We wish her all the best for her future career.

13.04.2025
 

The rapid growth of radiopharmaceutical sciences, driven by regulatory approvals of theranostic agents and the expanding role of PET imaging, underscores the need for sustainable and green practices. While radiopharmaceuticals offer high precision and targeted therapy with minimal systemic toxicity, the field faces challenges related to increasing demand, energy consumption, and waste management. As the field evolves, incorporating sustainability into training programs and research initiatives...

11.04.2025
 

Katharina Strauss defended her master thesis on the topic "Investigating Bioplastic Degradation Byproducts – Physicochemical Analysis and Ecocorona Formation". It was a pleasure to see your motivation and enthusiasm in the laboratory. We wish you all the Best for your future.

01.04.2025
 

We are always very grateful for the fatastic student exchanges we experience with our partner university Kaunas University of Technology. Thank you for being part of our laboratory, Daiana, we wish you all the Best to finish your studys back in Kaunas.

26.03.2025
 

I am very grateful to share our recent publication, where I had the pleasure of working with an incredible and inspiring team: Andreas Teuschl-Woller, Christian Kraule, Marcus Hacker and Chrysoula Vraka.

We introduce a cutting-edge bioanalytic hybrid system for preclinical radiotracer assessment! This innovative platform combines 3D cell cultures on a silk fibroin extracellular matrix with a chromatographic-like system.